These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28752465)

  • 21. Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature.
    Parr DG; Lara B
    Drug Des Devel Ther; 2017; 11():2149-2162. PubMed ID: 28769553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of augmentation therapy for alpha-1 antitrypsin deficiency.
    Mohanka M; Khemasuwan D; Stoller JK
    Expert Opin Biol Ther; 2012 Jun; 12(6):685-700. PubMed ID: 22500781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a survey of patients with alpha-1 antitrypsin deficiency.
    Strange C; Stoller JK; Sandhaus RA; Dickson R; Turino G
    Respiration; 2006; 73(2):185-90. PubMed ID: 16141711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
    Tonelli AR; Brantly ML
    Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of α1-antitrypsin deficiency.
    Stoller JK; Aboussouan LS
    Am J Respir Crit Care Med; 2012 Feb; 185(3):246-59. PubMed ID: 21960536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
    McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
    Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
    Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
    Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.
    Sandhaus RA; Turino G; Stocks J; Strange C; Trapnell BC; Silverman EK; Everett SE; Stoller JK;
    Chest; 2008 Oct; 134(4):831-834. PubMed ID: 18842915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha 1-antitrypsin augmentation therapy.
    Sandhaus RA
    Agents Actions Suppl; 1993; 42():97-102. PubMed ID: 8356934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune activation in α1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm.
    Baraldo S; Turato G; Lunardi F; Bazzan E; Schiavon M; Ferrarotti I; Molena B; Cazzuffi R; Damin M; Balestro E; Luisetti M; Rea F; Calabrese F; Cosio MG; Saetta M
    Am J Respir Crit Care Med; 2015 Feb; 191(4):402-9. PubMed ID: 25412116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema.
    Traclet J; Delaval P; Terrioux P; Mornex JF
    Rev Mal Respir; 2015 Apr; 32(4):435-46. PubMed ID: 25908241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Longterm Homecare Augmentation Program in Alpha-1-Antitrypsin Deficient Patients].
    Wilke A; Semper H; Gross C; Grohé C
    Pneumologie; 2018 Aug; 72(8):590-597. PubMed ID: 30089330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up.
    Schwaiblmair M; Vogelmeier C; Fruhmann G
    Respiration; 1997; 64(1):10-5. PubMed ID: 9044469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trials and Tribulations: An Industry Perspective on Conducting Registrational Trials in Alpha-1 Antitrypsin Deficiency.
    Forshag MS
    Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S374-7. PubMed ID: 27564675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema.
    Abboud RT; Vimalanathan S
    Int J Tuberc Lung Dis; 2008 Apr; 12(4):361-7. PubMed ID: 18371259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use.
    Karnaukhova E; Ophir Y; Golding B
    Amino Acids; 2006 Jun; 30(4):317-32. PubMed ID: 16773239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
    Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
    Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
    Casas F; Blanco I; Martínez MT; Bustamante A; Miravitlles M; Cadenas S; Hernández JM; Lázaro L; Rodríguez E; Rodríguez-Frías F; Torres M; Lara B
    Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease.
    Gadek JE; Fulmer JD; Gelfand JA; Frank MM; Petty TL; Crystal RG
    J Clin Invest; 1980 Jul; 66(1):82-87. PubMed ID: 6967489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Alpha-1 Antitrypsin Deficiency.
    Strange C; Beiko T
    Semin Respir Crit Care Med; 2015 Aug; 36(4):470-7. PubMed ID: 26238635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.